Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| KYNTRA BIO, INC.FGEN · Entity 7431 | Director · Chief Executive Officer | August 21, 2019 | August 23, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
KYNTRA BIO, INC.
Report date August 21, 2019 · Filed August 23, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 2,326,612 |
Ending reported balance
After 2019-08-22 transaction · row 6
5 source rows · reconciled sequenceRow 1 · 2019-08-21 · Exercise / conversion · Acquired 6,834 · Balance 2,356,578 Row 2 · 2019-08-21 · Sale · Disposed 18,400 · Balance 2,338,178 F1: Shares sold pursuant to a 10b5-1 plan. F2: The shares were sold at prices ranging from $44.54 to $45.12. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Row 4 · 2019-08-22 · Exercise / conversion · Acquired 6,834 · Balance 2,345,012 Row 5 · 2019-08-22 · Sale · Disposed 17,100 · Balance 2,327,912 F1: Shares sold pursuant to a 10b5-1 plan. F4: The shares were sold at prices ranging from $43.46 to $44.38. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Row 6 · 2019-08-22 · Sale · Disposed 1,300 · Balance 2,326,612 F1: Shares sold pursuant to a 10b5-1 plan. F5: The shares were sold at prices ranging from $44.61 to $44.95. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. |
| Common StockSEC Table I · non-derivative | IndirectBy Family Partnership | 45,656 |
Reported balance
After 2019-08-21 transaction · row 3
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 3 · 2019-08-21 · Sale · Disposed 1,418 · Balance 45,656 F1: Shares sold pursuant to a 10b5-1 plan. F3: The shares were sold at prices ranging from $44.51 to $45.115. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. |
| Common StockSEC Table I · non-derivative | IndirectBy Family Partnership | 44,238 |
Reported balance
After 2019-08-22 transaction · row 7
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 7 · 2019-08-22 · Sale · Disposed 1,418 · Balance 44,238 F1: Shares sold pursuant to a 10b5-1 plan. F6: The shares were sold at prices ranging from $43.47 to $43.95. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.90 · Expires 2020-06-09 | Direct | 184,536 |
Reported balance
After 2019-08-21 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2019-08-21 · Exercise / conversion · Disposed 6,834 · Balance 184,536 F8: Fully vested. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.90 · Expires 2020-06-09 | Direct | 177,702 |
Reported balance
After 2019-08-22 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2019-08-22 · Exercise / conversion · Disposed 6,834 · Balance 177,702 F8: Fully vested. |
| Common StockSEC Table I · non-derivative | IndirectBy Spouse | 20,000 |
Reported balance
Holding disclosure · report date 2019-08-21 · row 8
Holding and transaction disclosures are not merged.
1 source rowRow 8 · Balance 20,000 |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 60,946 |
Reported balance
Holding disclosure · report date 2019-08-21 · row 9
Holding and transaction disclosures are not merged.
1 source rowRow 9 · Balance 60,946 F7: The shares are held by BioGrowth Partners, LP. The reporting person is the sole general partner of BioGrowth Partners, LP and has sole voting and dispositive power over the shares held by BioGrowth Partners, LP. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares sold pursuant to a 10b5-1 plan.
F2: The shares were sold at prices ranging from $44.54 to $45.12. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
F3: The shares were sold at prices ranging from $44.51 to $45.115. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
F4: The shares were sold at prices ranging from $43.46 to $44.38. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
F5: The shares were sold at prices ranging from $44.61 to $44.95. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
F6: The shares were sold at prices ranging from $43.47 to $43.95. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
F7: The shares are held by BioGrowth Partners, LP. The reporting person is the sole general partner of BioGrowth Partners, LP and has sole voting and dispositive power over the shares held by BioGrowth Partners, LP.
F8: Fully vested.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 22, 2017 Filed Jun 23, 2017 20:38 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 418 | $32.02 | $13,384.36 |
DisclosureSEC source: 0001209191-17-041675 · doc4.xml · nonDerivative · entry 7 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Family Partnership Disclosed balance after: 136,710 F1 · shares: Shares sold pursuant to a 10b5-1 plan. F6 · price: The shares were sold at prices ranging from $31.85 to $32.425. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| June 22, 2017 Filed Jun 23, 2017 20:38 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 2,200 | $32.31 | $71,082.00 |
DisclosureSEC source: 0001209191-17-041675 · doc4.xml · nonDerivative · entry 6 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,311,880 F1 · shares: Shares sold pursuant to a 10b5-1 plan. F5 · price: The shares were sold at prices ranging from $32.15 to $32.45. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| June 22, 2017 Filed Jun 23, 2017 20:38 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 16,700 | $31.82 | $531,394.00 |
DisclosureSEC source: 0001209191-17-041675 · doc4.xml · nonDerivative · entry 5 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,314,080 F1 · shares: Shares sold pursuant to a 10b5-1 plan. F4 · price: The shares were sold at prices ranging from $31.15 to $32.10. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| June 22, 2017 Filed Jun 23, 2017 20:38 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionCommon Stock | 18,900 | $2.35 | $44,415.00 |
DisclosureSEC source: 0001209191-17-041675 · doc4.xml · nonDerivative · entry 4 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,330,780 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 21, 2017 Filed Jun 23, 2017 20:38 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionStock Option (Right to Buy) · Derivative | 18,900 | $0.00 Strike: $2.35 | $0.00 |
DisclosureSEC source: 0001209191-17-041675 · doc4.xml · derivative · entry 10 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 168,724 Underlying: Common Stock · 18,900 shares Expires 2018-03-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_date: Fully vested. Read SEC document |
| June 21, 2017 Filed Jun 23, 2017 20:38 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 418 | $31.22 | $13,049.96 |
DisclosureSEC source: 0001209191-17-041675 · doc4.xml · nonDerivative · entry 3 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Family Partnership Disclosed balance after: 137,128 F1 · shares: Shares sold pursuant to a 10b5-1 plan. F3 · price: The shares were sold at prices ranging from $30.90 to $31.50. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| June 21, 2017 Filed Jun 23, 2017 20:38 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 18,900 | $31.15 | $588,735.00 |
DisclosureSEC source: 0001209191-17-041675 · doc4.xml · nonDerivative · entry 2 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,311,880 F1 · shares: Shares sold pursuant to a 10b5-1 plan. F2 · price: The shares were sold at prices ranging from $30.70 to $31.60. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| June 21, 2017 Filed Jun 23, 2017 20:38 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionCommon Stock | 18,900 | $2.35 | $44,415.00 |
DisclosureSEC source: 0001209191-17-041675 · doc4.xml · nonDerivative · entry 1 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,330,780 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 16, 2017 Filed Jun 19, 2017 21:49 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionStock Option (Right to Buy) · Derivative | 18,900 | $0.00 Strike: $2.35 | $0.00 |
DisclosureSEC source: 0001209191-17-040903 · doc4.xml · derivative · entry 10 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 187,624 Underlying: Common Stock · 18,900 shares Expires 2018-03-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: Fully vested. Read SEC document |
| June 16, 2017 Filed Jun 19, 2017 21:49 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 418 | $29.58 | $12,364.44 |
DisclosureSEC source: 0001209191-17-040903 · doc4.xml · nonDerivative · entry 6 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Family Partnership Disclosed balance after: 137,546 F1 · shares: Shares sold pursuant to a 10b5-1 plan. F5 · price: The shares were sold at prices ranging from $29.45 to $29.65. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| June 16, 2017 Filed Jun 19, 2017 21:49 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 18,900 | $29.54 | $558,306.00 |
DisclosureSEC source: 0001209191-17-040903 · doc4.xml · nonDerivative · entry 5 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,311,880 F1 · shares: Shares sold pursuant to a 10b5-1 plan. F4 · price: The shares were sold at prices ranging from $29.15 to $29.75. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| June 16, 2017 Filed Jun 19, 2017 21:49 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionCommon Stock | 18,900 | $2.35 | $44,415.00 |
DisclosureSEC source: 0001209191-17-040903 · doc4.xml · nonDerivative · entry 4 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,330,780 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 15, 2017 Filed Jun 19, 2017 21:49 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionStock Option (Right to Buy) · Derivative | 11,689 | $0.00 Strike: $2.35 | $0.00 |
DisclosureSEC source: 0001209191-17-040903 · doc4.xml · derivative · entry 9 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 206,524 Underlying: Common Stock · 11,689 shares Expires 2018-03-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: Fully vested. Read SEC document |
| June 15, 2017 Filed Jun 19, 2017 21:49 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 418 | $29.28 | $12,239.04 |
DisclosureSEC source: 0001209191-17-040903 · doc4.xml · nonDerivative · entry 3 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Family Partnership Disclosed balance after: 137,964 F1 · shares: Shares sold pursuant to a 10b5-1 plan. F3 · price: The shares were sold at prices ranging from $29.15 to $29.40. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| June 15, 2017 Filed Jun 19, 2017 21:49 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 18,900 | $29.25 | $552,825.00 |
DisclosureSEC source: 0001209191-17-040903 · doc4.xml · nonDerivative · entry 2 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,311,880 F1 · shares: Shares sold pursuant to a 10b5-1 plan. F2 · price: The shares were sold at prices ranging from $28.65 to $29.45. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| June 15, 2017 Filed Jun 19, 2017 21:49 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionCommon Stock | 11,689 | $2.35 | $27,469.15 |
DisclosureSEC source: 0001209191-17-040903 · doc4.xml · nonDerivative · entry 1 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,330,780 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 06, 2017 Filed Jun 8, 2017 23:35 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Tax withholdingCommon Stock | 3,261 | $29.05 | $94,732.05 |
DisclosureSEC source: 0001209191-17-038673 · doc4.xml · nonDerivative · entry 1 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,319,091 F1 · shares: Represents shares withheld by the issuer to satisfy a tax obligation realized by the reporting person upon the vesting of restricted stock units. Read SEC document |
| June 01, 2017 Filed Jun 1, 2017 23:23 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Tax withholdingCommon Stock | 4,689 | $27.60 | $129,416.40 |
DisclosureSEC source: 0001209191-17-036942 · doc4.xml · nonDerivative · entry 8 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,322,352 F7 · shares: Represents shares withheld by the issuer to satisfy a tax obligation realized by the reporting person upon the vesting of restricted stock units. Read SEC document |
| May 31, 2017 Filed Jun 1, 2017 23:23 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionStock Option (Right to Buy) · Derivative | 18,900 | $0.00 Strike: $2.35 | $0.00 |
DisclosureSEC source: 0001209191-17-036942 · doc4.xml · derivative · entry 12 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 218,213 Underlying: Common Stock · 18,900 shares Expires 2018-03-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_date: Fully vested. Read SEC document |
| May 31, 2017 Filed Jun 1, 2017 23:23 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 418 | $26.03 | $10,880.54 |
DisclosureSEC source: 0001209191-17-036942 · doc4.xml · nonDerivative · entry 7 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Family Partnership Disclosed balance after: 138,382 F1 · shares: Shares sold pursuant to a 10b5-1 plan. F6 · price: The shares were sold at prices ranging from $25.75 to $26.30. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| May 31, 2017 Filed Jun 1, 2017 23:23 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 18,900 | $25.97 | $490,833.00 |
DisclosureSEC source: 0001209191-17-036942 · doc4.xml · nonDerivative · entry 6 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,327,041 F1 · shares: Shares sold pursuant to a 10b5-1 plan. F5 · price: The shares were sold at prices ranging from $25.35 to $26.35. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| May 31, 2017 Filed Jun 1, 2017 23:23 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionCommon Stock | 18,900 | $2.35 | $44,415.00 |
DisclosureSEC source: 0001209191-17-036942 · doc4.xml · nonDerivative · entry 5 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,345,941 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 30, 2017 Filed Jun 1, 2017 23:23 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionStock Option (Right to Buy) · Derivative | 18,900 | $0.00 Strike: $2.35 | $0.00 |
DisclosureSEC source: 0001209191-17-036942 · doc4.xml · derivative · entry 11 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 237,113 Underlying: Common Stock · 18,900 shares Expires 2018-03-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_date: Fully vested. Read SEC document |
| May 30, 2017 Filed Jun 1, 2017 23:23 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 418 | $26.30 | $10,993.40 |
DisclosureSEC source: 0001209191-17-036942 · doc4.xml · nonDerivative · entry 4 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Family Partnership Disclosed balance after: 138,800 F1 · shares: Shares sold pursuant to a 10b5-1 plan. F4 · price: The shares were sold at prices ranging from $25.85 to $26.85. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| May 30, 2017 Filed Jun 1, 2017 23:23 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 7,500 | $26.88 | $201,600.00 |
DisclosureSEC source: 0001209191-17-036942 · doc4.xml · nonDerivative · entry 3 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,327,041 F1 · shares: Shares sold pursuant to a 10b5-1 plan. F3 · price: The shares were sold at prices ranging from $26.70 to $27.15. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| May 30, 2017 Filed Jun 1, 2017 23:23 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 11,400 | $26.16 | $298,224.00 |
DisclosureSEC source: 0001209191-17-036942 · doc4.xml · nonDerivative · entry 2 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,334,541 F1 · shares: Shares sold pursuant to a 10b5-1 plan. F2 · price: The shares were sold at prices ranging from $25.70 to $26.65. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| May 30, 2017 Filed Jun 1, 2017 23:23 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionCommon Stock | 18,900 | $2.35 | $44,415.00 |
DisclosureSEC source: 0001209191-17-036942 · doc4.xml · nonDerivative · entry 1 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,345,941 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 16, 2017 Filed May 18, 2017 00:52 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionStock Option (Right to Buy) · Derivative | 18,900 | $0.00 Strike: $2.35 | $0.00 |
DisclosureSEC source: 0001209191-17-033459 · doc4.xml · derivative · entry 10 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 256,013 Underlying: Common Stock · 18,900 shares Expires 2018-03-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: Fully vested. Read SEC document |
| May 16, 2017 Filed May 18, 2017 00:52 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 418 | $27.67 | $11,566.06 |
DisclosureSEC source: 0001209191-17-033459 · doc4.xml · nonDerivative · entry 6 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Family Partnership Disclosed balance after: 139,218 F1 · shares: Shares sold pursuant to a 10b5-1 plan. F5 · price: The shares were sold at prices ranging from $27.40 to $27.90. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| May 16, 2017 Filed May 18, 2017 00:52 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 18,900 | $27.64 | $522,396.00 |
DisclosureSEC source: 0001209191-17-033459 · doc4.xml · nonDerivative · entry 5 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,327,041 F1 · shares: Shares sold pursuant to a 10b5-1 plan. F4 · price: The shares were sold at prices ranging from $27.35 to $27.875. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| May 16, 2017 Filed May 18, 2017 00:52 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionCommon Stock | 18,900 | $2.35 | $44,415.00 |
DisclosureSEC source: 0001209191-17-033459 · doc4.xml · nonDerivative · entry 4 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,345,941 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 15, 2017 Filed May 18, 2017 00:52 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionStock Option (Right to Buy) · Derivative | 18,900 | $0.00 Strike: $2.35 | $0.00 |
DisclosureSEC source: 0001209191-17-033459 · doc4.xml · derivative · entry 9 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 274,913 Underlying: Common Stock · 18,900 shares Expires 2018-03-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: Fully vested. Read SEC document |
| May 15, 2017 Filed May 18, 2017 00:52 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 418 | $27.81 | $11,624.58 |
DisclosureSEC source: 0001209191-17-033459 · doc4.xml · nonDerivative · entry 3 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Family Partnership Disclosed balance after: 139,636 F1 · shares: Shares sold pursuant to a 10b5-1 plan. F3 · price: The shares were sold at prices ranging from $27.70 to $27.875. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| May 15, 2017 Filed May 18, 2017 00:52 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 18,900 | $27.75 | $524,475.00 |
DisclosureSEC source: 0001209191-17-033459 · doc4.xml · nonDerivative · entry 2 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,327,041 F1 · shares: Shares sold pursuant to a 10b5-1 plan. F2 · price: The shares were sold at prices ranging from $27.45 to $27.90. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| May 15, 2017 Filed May 18, 2017 00:52 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionCommon Stock | 18,900 | $2.35 | $44,415.00 |
DisclosureSEC source: 0001209191-17-033459 · doc4.xml · nonDerivative · entry 1 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,345,941 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 25, 2017 Filed Apr 26, 2017 23:31 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,106 | $0.00 Strike: $2.35 | $0.00 |
DisclosureSEC source: 0001209191-17-028272 · doc4.xml · derivative · entry 12 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 293,813 Underlying: Common Stock · 10,106 shares Expires 2018-03-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: Fully vested. Read SEC document |
| April 25, 2017 Filed Apr 26, 2017 23:31 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionStock Option (Right to Buy) · Derivative | 8,794 | $0.00 Strike: $4.03 | $0.00 |
DisclosureSEC source: 0001209191-17-028272 · doc4.xml · derivative · entry 11 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,794 shares Expires 2017-08-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: Fully vested. Read SEC document |
| April 25, 2017 Filed Apr 26, 2017 23:31 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 418 | $27.67 | $11,566.06 |
DisclosureSEC source: 0001209191-17-028272 · doc4.xml · nonDerivative · entry 7 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Family Partnership Disclosed balance after: 140,054 F1 · shares: Shares sold pursuant to a 10b5-1 plan. F5 · price: The shares were sold at prices ranging from $27.475 to $27.925. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| April 25, 2017 Filed Apr 26, 2017 23:31 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 18,900 | $27.49 | $519,561.00 |
DisclosureSEC source: 0001209191-17-028272 · doc4.xml · nonDerivative · entry 6 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,327,041 F1 · shares: Shares sold pursuant to a 10b5-1 plan. F4 · price: The shares were sold at prices ranging from $27.00 to $27.925. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| April 25, 2017 Filed Apr 26, 2017 23:31 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionCommon Stock | 10,106 | $2.35 | $23,749.10 |
DisclosureSEC source: 0001209191-17-028272 · doc4.xml · nonDerivative · entry 5 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,345,941 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 25, 2017 Filed Apr 26, 2017 23:31 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionCommon Stock | 8,794 | $4.03 | $35,395.85 |
DisclosureSEC source: 0001209191-17-028272 · doc4.xml · nonDerivative · entry 4 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,335,835 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 24, 2017 Filed Apr 26, 2017 23:31 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionStock Option (Right to Buy) · Derivative | 18,900 | $0.00 Strike: $4.03 | $0.00 |
DisclosureSEC source: 0001209191-17-028272 · doc4.xml · derivative · entry 10 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,794 Underlying: Common Stock · 18,900 shares Expires 2017-08-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: Fully vested. Read SEC document |
| April 24, 2017 Filed Apr 26, 2017 23:31 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 418 | $26.45 | $11,056.10 |
DisclosureSEC source: 0001209191-17-028272 · doc4.xml · nonDerivative · entry 3 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Family Partnership Disclosed balance after: 140,472 F1 · shares: Shares sold pursuant to a 10b5-1 plan. F3 · price: The shares were sold at prices ranging from $26.30 to $26.55. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| April 24, 2017 Filed Apr 26, 2017 23:31 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 18,900 | $26.35 | $498,015.00 |
DisclosureSEC source: 0001209191-17-028272 · doc4.xml · nonDerivative · entry 2 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,327,041 F1 · shares: Shares sold pursuant to a 10b5-1 plan. F2 · price: The shares were sold at prices ranging from $25.95 to $26.60. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| April 24, 2017 Filed Apr 26, 2017 23:31 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionCommon Stock | 18,900 | $4.03 | $76,072.50 |
DisclosureSEC source: 0001209191-17-028272 · doc4.xml · nonDerivative · entry 1 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,345,941 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 13, 2017 Filed Apr 14, 2017 22:06 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionStock Option (Right to Buy) · Derivative | 18,900 | $0.00 Strike: $4.03 | $0.00 |
DisclosureSEC source: 0001209191-17-026994 · doc4.xml · derivative · entry 11 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,694 Underlying: Common Stock · 18,900 shares Expires 2017-08-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_date: Fully vested. Read SEC document |
| April 13, 2017 Filed Apr 14, 2017 22:06 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 418 | $24.95 | $10,429.10 |
DisclosureSEC source: 0001209191-17-026994 · doc4.xml · nonDerivative · entry 7 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Family Partnership Disclosed balance after: 140,890 F1 · shares: Shares sold pursuant to a 10b5-1 plan. F6 · price: The shares were sold at prices ranging from $24.65 to $25.30. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| April 13, 2017 Filed Apr 14, 2017 22:06 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 18,900 | $24.91 | $470,799.00 |
DisclosureSEC source: 0001209191-17-026994 · doc4.xml · nonDerivative · entry 6 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,327,041 F1 · shares: Shares sold pursuant to a 10b5-1 plan. F5 · price: The shares were sold at prices ranging from $24.50 to $25.35. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| April 13, 2017 Filed Apr 14, 2017 22:06 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionCommon Stock | 18,900 | $4.03 | $76,072.50 |
DisclosureSEC source: 0001209191-17-026994 · doc4.xml · nonDerivative · entry 5 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,345,941 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 12, 2017 Filed Apr 14, 2017 22:06 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionStock Options (Right to Buy) · Derivative | 18,900 | $0.00 Strike: $4.03 | $0.00 |
DisclosureSEC source: 0001209191-17-026994 · doc4.xml · derivative · entry 10 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,594 Underlying: Common Stock · 18,900 shares Expires 2017-08-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_date: Fully vested. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.